References
- Mosbech H, Deckelmann R, de Blay F, et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2014;134:568-75.e7
- Poole CD, Bannister CA, Andreasen JN, Andersen JS, Currie CJ. Estimation of health-related utility (EQ-5D index) in subjects with seasonal allergic rhinoconjunctivitis to evaluate health gain associated with sublingual grass allergen immunotherapy. Health Qual Life Outcomes 2014;12:99
- Hellgren J, Cervin A, Nordling S, Bergman A, Cardell LO. Allergic rhinitis and the common cold–high cost to society. Allergy 2010;65:776-83
- U.S. National Institutes of Health. ClinicalTrials.gov. http://clinicaltrials.gov. Search: house AND dust AND mite AND allergy. Accessed September 12, 2014
- Emminger W, Smeenk F, Guzik T, et al. Abstract 417 The SQ HDM SLIT-tablet is well-tolerated in respiratory allergic disease; results from 2 DBPC phase III trials (MERIT and MITRA). Allergy 2014;69(99 Suppl):111-99
- Hernández D, Mosbech H, Dichmann R, et al. Abstract 421 SQ HDM SLIT-tablet induces significant immunomodulatory response; results from a DBPC phase III trial (MITRA). Allergy 2014;69(99 Suppl):111-99
- Horak F, Maloney J, Nelson S, et al. Abstract 1778 Onset of action of house dust mite sublingual immunotherapy tablet (SLIT-T) using an environmental exposure chamber. Allergy 2014;69(99 Suppl):573-619
- Demoly P, Decot E, Lozovskis V, et al. Abstract 415 Effective treatment of house dust mite (HDM) allergic rhinitis with the SQ HDM SLIT-tablet; results from a DBPC phase III trial (MERIT). Allergy 2014;69(99 Suppl):111-99
- Virchow J, Backer V, Kuna P, et al. Abstract 414 SQ HDM SLIT-tablet is effective in the treatment of allergic asthma; results from a DBPC phase III trial (MITRA). Allergy 2014;69(99 Suppl):111-99
- Maloney J, Prenner BM, Bernstein DI, et al. Safety of house dust mite sublingual immunotherapy standardized quality tablet in children allergic to house dust mites. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol 2016;116:59-65
- JAPIC Clinical Trials Information. Torii TO-203. JapicCTI number 121848. http://www.clinicaltrials.jp. Accessed December 2015
- Nelson HS. Subcutaneous immunotherapy versus sublingual immunotherapy: which is more effective? J Allergy Clin Immunol Pract 2014;2:144-9
- Calderon MA, Casale TB, Nelson HS, et al. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies. J Allergy Clin Immunol 2013;132:1322-36
- Blumberga G, Groes L, Haugaard L, et al. Steroid-sparing effect of subcutaneous SQ-standardised specific immunotherapy in moderate and severe house dust mite allergic asthmatics. Allergy 2006;61:843-8
- Zielen S, Kardos P, Madonini E. Steroid-sparing effects with allergen-specific immunotherapy in children with asthma: a randomized controlled trial. J Allergy Clin Immunol 2010;126:942-9
- Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. Oxford University Press, 2005. Oxford, UK
- Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health J Int Soc Pharmacoeconomics Outcomes Res 2014;17:5-14
- Focus group meeting conducted by ALK with participation of physicians with knowledge about treatments with SCIT and SLIT-tablets. 2014
- Lægemiddelstyrelsen. www.medicinpriser.dk. Accessed December, 2015.
- Lægeforeningen. www.laeger.dk. Accessed December, 2015
- Sundhedsdatastyrelsen. www.drg.dk. Accessed December, 2015
- Danmarks Statistik. www.statistikbanken.dk. Accessed December, 2015.
- Skat. www.skat.dk. Accessed December, 2015
- DSI Institut for Sundhedsvæsen. Standardiseret rapporteringsstruktur for sundhedsøkonomiske analyser i ansøgninger om generelt tilskud til lægemidler. Lægemiddelstyrelsen. Copenhagen 2004.
- Lægemiddelstyrelsen, for Sundhedsvæsen DI. Erfaringer med sundhedsøkonomiske analyser i ansøgninger om generelt tilskud til lægemidler. 2011
- Hankin CS, Cox L. Allergy immunotherapy: what is the evidence for cost saving? Curr Opin Allergy Clin Immunol 2014;14:363-70
- Andreasen J, Lawton S, Bæch S, Svärd M. Compliance and persistence to Grass Immunotherapy Treatment is comparable for allergy immunotherapy tablets and subcutaneous immunotherapy: a Swedish Registry Study. World Allergy Organ J 2012;5(2 Suppl):S86
- Bahceciler NN, Babayigit Hocaoglu A, Galip N. A milestone in house dust-mite-allergen immunotherapy: the new sublingual tablet S-524101 (actair). Expert Rev Vaccines 2014;13:1427-38